Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific

Executive Summary

Starts & Stops is a regular feature highlighting Medtech Insight's monthly picks of noteworthy clinical trial announcements, initiations, completions, and suspensions. The list for December is headlined by announcements on Edwards' transcatheter valve technologies. Meanwhile, MValve, a company Boston Scientific has invested in, is not going forward with a planned trial of its MValve dock device with Boston Scientific's Lotus valve, which is currently off the market.

You may also be interested in...



Edwards Discontinues Centera TAVR Program As Sapien Sales Continue To Climb

Edwards Lifesciences is giving up on the Centera transcatheter aortic valve replacement (TAVR), despite promising clinical results, to focus on its Sapien TAVR line. The company reported overall revenue of $1.1bn in the second quarter of 2019, representing 14% year-over-year growth, driven by 18% growth in sales of Sapien systems.

Edwards’ Pascal Improves Mitral Regurgitation In Early Trial Results

One-month results from the CLASP trial, presented at the German Cardiology Meeting (DGK), show Edwards’ Pascal mitral valve repair device reduces mitral regurgitation in heart failure patients with moderate to severe mitral regurgitation.

Medtronic Confident Renal Denervation Trial Will Work This Time

US FDA has approved Medtronic's plan for the SPYRAL HTN Pivotal Trial, part of the SPYRAL HTN Global Clinical Program. SPYRAL HTN is a multi-phased clinical study strategy to establish the safety and efficacy of renal denervation with the Symplicity Spyral system to reduce blood pressure in patients with uncontrolled hypertension. The Spyral device and procedure, as well as the design of the SPYRAL HTN clinical trial, reflect lessons learned from SYMPLICITY HTN-3, the first sham-controlled trial of renal denervation, which famously failed to show a benefit of the procedure.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel